Arcutis Biotherapeutics, Inc. Common Stock
ARQT Real Time Price USDRecent trades of ARQT by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ARQT's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
ARQT Revenue by Segment or Geography
New patents grants
-
Patent Title: Inhibition of crystal growth of roflumilast Mar. 25, 2025
-
Patent Title: Roflumilast formulations with an improved pharmacokinetic profile Feb. 11, 2025
-
Patent Title: Stable formulations of shr0302 Dec. 10, 2024
-
Patent Title: Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug Nov. 19, 2024
-
Patent Title: Laureth-4 containing topical formulations Sep. 10, 2024
-
Patent Title: Compositions and methods for deep dermal drug delivery Aug. 06, 2024
-
Patent Title: Method and formulation for improving roflumilast skin penetration lag time Jul. 23, 2024
-
Patent Title: Method for reducing side effects from administration of phosphodiesterase-4 inhibitors Jul. 23, 2024
-
Patent Title: Roflumilast formulations with an improved pharmacokinetic profile Jun. 25, 2024
-
Patent Title: Roflumilast formulations with an improved pharmacokinetic profile Jun. 18, 2024
-
Patent Title: Topical roflumilast formulation having improved delivery and plasma half-life Jun. 11, 2024
-
Patent Title: Topical roflumilast formulation having improved delivery and plasma half life Jun. 11, 2024
-
Patent Title: Method for reducing side effects from administration of phosphodiesterase-4 inhibitors May. 28, 2024
-
Patent Title: Topical roflumilast formulation having improved delivery and plasma half-life Nov. 21, 2023
-
Patent Title: Inhibition of crystal growth of roflumilast Oct. 24, 2023
-
Patent Title: Laureth-4 containing topical formulations Aug. 22, 2023
-
Patent Title: Topical roflumilast formulation having antifungal properties Jul. 25, 2023
-
Patent Title: Compositions and methods for deep dermal drug delivery Apr. 18, 2023
-
Patent Title: Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents Dec. 27, 2022
-
Patent Title: Topical roflumilast formulation having improved delivery and plasma half life Sep. 28, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to ARQT
Recent picks made for ARQT stock on CNBC
ETFs with the largest estimated holdings in ARQT
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ARQT stock a Buy, Sell, or Hold?
- What is the price target for $ARQT stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ARQT stock?
- Who owns the most shares of $ARQT stock?
- What funds own $ARQT stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ARQT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.